Erratum to: Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data [BMC Med, 13, (2015) (227)], DOI:10.1186/s12916-015-0456-7;Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: A systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Ashley, Elizabeth A ^a,b   Aweeka, Francesca ^c   Barnes, Karen I ^d,e   Bassat, Quique ^f,g   Borrmann, Steffen ^h,i   Dahal, Prabin ^d,j   Davis, Timothy M E ^k   Denis, Mey Bouth ^n,o   Djimde, Abdoulaye A ^p   Faucher, Jean François ^l,q   Genton, Blaise ^r,s   Guérin, Philippe J ^d,j   Hamed, Kamal ^t   Hodel, Eva Maria ^r,u   Huang, Liusheng ^c   Jullien, Vincent ^v   Karunajeewa, Harin A ^k   Kiechel, Jean René ^w   Kofoed, Poul Erik ^x,y   Lefèvre, Gilbert ^t   Lindegardh, Niklas Lindegardh ^ae   Mårtensson, Andreas ^z   Mayxay, Mayfong ^aa   Mcgready, Rose ^a,b   Moreira, Clarissa ^ac   Newton, Paul N ^j,ab   Ngasala, Billy E ^aa,ac   Nosten, Francois ^a,b,j   Nsanzabana, Christian ^d,j   Parikh, Sunil ^ad,ae   Piola, Patrice ^d,af   Price, Ric N ^d,j,ag   Ringwald, Pascal ^o   Rombo, Lars ^aa,ai   Schramm, Birgit ^ah   Sibley, Carol Hopkins ^d,aj   Stepniewska, Kasia ^d,j   Tarning, Joel ^b,d,j   Ursing, Johan ^aa   Van Vugt, Michele ^ak   White, Nicholas J ^b   Workman, Lesley J ^d,e,j   Deloron, Philippe ^l,m   Marsh, Kevin ^j   more..

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WorldWide Antimalarial Resistance Network   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF BARCELONA   (Spain)

^g Manhiça Health Research Center   (Mozambique)

^h KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

ⁱ UNIVERSITY OF TÜBINGEN   (Germany)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^l INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ Entomology and Malaria Control   (Cambodia)

^o WORLD HEALTH ORGANIZATION   (Switzerland)

^p UNIVERSITY OF BAMAKO   (Mali)

^q UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^r SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^s LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^t NOVARTIS PHARMA AG   (Switzerland)

^u LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^v INSERM   (France)

^w Drugs for Neglected Diseases Initiative   (Switzerland)

^x UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^y KOLDING HOSPITAL   (Denmark)

^z KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^aa KAROLINSKA INSTITUTE   (Sweden)

^ab WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^ac MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^ad YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^ae Mahosot Hospital ^*

^af INSTITUT PASTEUR DE MADAGASCAR   (Madagascar)

^ag MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^ah UPPSALA UNIVERSITY   (Sweden)

^ai EPICENTRE   (France)

^aj UNIVERSITY OF WASHINGTON   (United States)

^ak UNIVERSITY OF AMSTERDAM   (Netherlands)

more..

Author keywords

Artemether lumefantrine; Baseline parasitemia; Day 7 lumefantrine concentration; Drug resistance; Early parasitological response; Malnutrition; Meta analysis; Pharmacodynamic; Pharmacokinetic; Uncomplicated Plasmodium falciparum malaria

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; BENFLUMETOL;

ARTICLE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; HUMAN; MALARIA FALCIPARUM; META ANALYSIS; PARASITE TRANSMISSION; PARASITEMIA; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; SYSTEMATIC REVIEW;

EID: 84942087456     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0757-5     Document Type: Erratum

References (91)

1. World Health Organization (WHO). Guidelines for the treatment of malaria. 3rd ed. Geneva: WHO; 2015. http://www.who.int/malaria/publications/atoz/9789241549127/en/.
2. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level Trends Parasitol. 2008;24:159-63.
3. Barnes KI, Lindegardh N, Ogundahunsi O, Olliaro P, Plowe CV, Randrianarivelojosia M, et al. World Antimalarial Resistance Network (WARN) IV: clinical pharmacology. Malar J. 2007;6:122.
4. World Health Organization (WHO). World malaria report 2014. Geneva: WHO; 2014. http://www.who.int/malaria/publications/world_malaria_report_2014/report/en/.
5. Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54:52-9.
6. White NJ, van Vugt M, Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet. 1999;37:105-25.
7. Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother. 2000;44:697-704.
8. McGready R, Tan SO, Ashley EA, Pimanpanarak M, Viladpai-Nguen J, Phaiphun L, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5:e253.
9. Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5:59.
10. Rahman MM, Dondorp AM, Day NP, Lindegardh N, Imwong M, Faiz MA, et al. Adherence and efficacy of supervised versus non-supervised treatment with artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bangladesh: a randomised controlled trial. Trans R Soc Trop Med Hyg. 2008;102:861-7.
11. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis. 2006;42:1570-7.
12. Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Heal. 2006;11:1800-7.
13. Mosha D, Guidi M, Mwingira F, Abdulla S, Mercier T, Decosterd LA, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58:4583-92.
14. Kloprogge F, Piola P, Dhorda M, Muwanga S, Turyakira E, Apinan S, et al. Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. CPT Pharmacometrics Syst Pharmacol. 2013;2:e83.
15. Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009;53:3837-46.
16. McGready R, Stepniewska K, Lindegardh N, Ashley EA, La Y, Singhasivanon P, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62:1021-31.
17. Piola P, Nabasumba C, Turyakira E, Dhorda M, Lindegardh N, Nyehangane D, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2010;10:762-9.
18. Ashley EA, Stepniewska K, Lindegardh N, Annerberg A, Kham A, Brockman A, et al. How much fat is necessary to optimize lumefantrine oral bioavailability Trop Med Int Heal. 2007;12:195.
19. Achan J, Kakuru A, Ikilezi G, Ruel T, Clark TD, Nsanzabana C, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med. 2012;367:2110-8.
20. Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother. 2012;67:2213-21.
21. Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. J Acquir Immune Defic Syndr. 2012;61:310-6.
22. Lamorde M, Byakika-Kibwika P, Mayito J, Nabukeera L, Ryan M, Hanpithakpong W, et al. Lower artemether, dihydroartemisinin and lumefantrine concentrations during rifampicin-based tuberculosis treatment. AIDS. 2013;27:961-5.
23. Lefevre G, Bindschedler M, Ezzet F, Schaeffer N, Meyer I, Thomsen MS. Pharmacokinetic interaction trial between co-artemether and mefloquine. Eur J Pharm Sci. 2000;10:141-51.
24. WorldWide Antimalarial Resistance Network (WWARN). The WWARN project terms of submission. Oxford: WWARN; 2013. http://www.wwarn.org/sites/default/files/TermsOfSubmission.pdf.
25. WorldWide Antimalarial Resistance Network (WWARN). Clinical module: data management and statistical analysis plan. Version 1.2. Oxford: WWARN; 2012. http://www.wwarn.org/sites/default/files/ClinicalDMSAP.pdf.
26. WorldWide Antimalarial Resistance Network (WWARN). Pharmacology module: data management and statistical analysis plan (DMSAP). Version 1.0. Oxford: WWARN; 2011. http://www.wwarn.org/sites/default/files/PharmacologyDMSAP.pdf.
27. Vugt MV, Wilairatana P, Gemperli B, Gathmann I, Phaipun L, Brockman A, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg. 1999;60:936-42.
28. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County. Liberia Malar J. 2013;12:250.
29. Dorsey G, Staedke S, Clark TD, Njama-Meya D, Nzarubara B, Maiteki-Sebuguzi C, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA. 2007;297:2210-9.
30. van Vugt M, Looareesuwan S, Wilairatana P, McGready R, Villegas L, Gathmann I, et al. Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94:545-8.
31. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Effectiveness of artemether-lumefantrine provided by community health workers in under-five children with uncomplicated malaria in rural Tanzania: an open label prospective study. Malar J. 2011;10:64.
32. Ngasala BE, Malmberg M, Carlsson AM, Ferreira PE, Petzold MG, Blessborn D, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis. 2011;52:873-82.
33. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, et al. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med. 2008;359:2545-57.
34. Ursing J, Kofoed PE, Rodrigues A, Blessborn D, Thoft-Nielsen R, Bjorkman A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2011;203:109-16.
35. Salman S, Page-Sharp M, Griffin S, Kose K, Siba PM, Ilett KF, et al. Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother. 2011;55:5306-13.
36. van Vugt M, Brockman A, Gemperli B, Luxemburger C, Gathmann I, Royce C, et al. Randomized comparison of artemether-benflumetol and artesunate-mefloquine in treatment of multidrug-resistant falciparum malaria. Antimicrob Agents Chemother. 1998;42:135-9.
37. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005;365:1467-73.
38. Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, et al. Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority. Malar J. 2013;12:251.
39. Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of Plasmodium falciparum infections to artemisinin-based combination treatments on the Kenyan coast. PLoS One. 2011;6:e26005.
40. Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, Hutagalung R, et al. Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health. 2007;12:201-8.
41. Mayxay M, Khanthavong M, Lindegardh N, Keola S, Barends M, Pongvongsa T, et al. Randomized comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic. Clin Infect Dis. 2004;39:1139-47.
42. Hodel EM, Kabanywanyi AM, Malila A, Zanolari B, Mercier T, Beck HP, et al. Residual antimalarials in malaria patients from Tanzania--implications on drug efficacy assessment and spread of parasite resistance. PLoS One. 2009;4:e8184.
43. Faucher JF, Aubouy A, Adeothy A, Cottrell G, Doritchamou J, Gourmel B, et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated plasmodium falciparum malaria in Benin: a randomized effectiveness noninferiority trial. J Infect Dis. 2009;200:57-65.
44. Djimde AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2011;55:3994-9.
45. Lindegardh N, Annerberg A, Blessborn D, Bergqvist Y, Day N, White NJ. Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. J Pharm Biomed Anal. 2005;37:1081-8.
46. Zeng MY. Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1996;7:229-306.
47. Blessborn D, Romsing S, Annerberg A, Sundquist D, Bjorkman A, Lindegardh N, et al. Development and validation of an automated solid-phase extraction and liquid chromatographic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal. 2007;45:282-7.
48. Mansoor SM. Determination of a new antimalarial drug, benflumetol, in blood plasma by high-performance liquid chromatography. J Chromatogr B Biomed Appl. 1996;12:321-5.
49. Hodel EM, Zanolari B, Mercier T, Biollaz J, Keiser J, Olliaro P, et al. A single LC-tandem mass spectrometry method for the simultaneous determination of 14 antimalarial drugs and their metabolites in human plasma. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:867-86.
50. Wong RP, Salman S, Ilett KF, Siba PM, Mueller I, Davis TM. Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome. Antimicrob Agents Chemother. 2011;55:1194-8.
51. Annerberg A, Singtoroj T, Tipmanee P, White NJ, Day NPJ, Lindegardh N. High throughput assay for the determination of lumefantrine in plasma. J Chromatogr B-Analytical Technol Biomed Life Sci. 2005;822:330-3.
52. WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK/PD Study Group. Statistical analysis plan. Version 1.0. Oxford: WWARN; 2012. http://www.wwarn.org/sites/default/files/attachments/documents/lumefantrinepkpdday7studygroupsap_4.pdf.
53. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481-504.
54. World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and mineral nutrition information system. Geneva: WHO; 2011. http://www.who.int/vmnis/indicators/haemoglobin.pdf.
55. Lee SJ, Stepniewska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J. 2008;7:149.
56. WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Geneva: WHO; 2006. http://www.who.int/childgrowth/standards/technical_report/en/.
57. Gething PW, Patil AP, Smith DL, Guerra CA, Elyazar IR, Johnston GL, et al. A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J. 2011;10:378.
58. Stepniewska K, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, et al. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis. 2010;201:570-9.
59. World Health Organization (WHO). Methods for surveillance of antimalarial drug efficacy. Geneva: WHO; 2009. http://whqlibdoc.who.int/publications/2009/9789241597531_eng.pdf.
60. Glidden DV, Vittinghoff E. Modelling clustered survival data from multicentre clinical trials. Stat Med. 2004;23:369-88.
61. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69:239-41.
62. Royston P, Altman DG. Regression using fractional polynomials of continuous covariate: Parsimonios parametric modelling. Appl Stat. 1994;43:429-67.
63. Little RJA, Rubin D. Statistical analysis with missing data. New York, NY: John Wiley & Sons; 1987.
64. Stohrer JM, Dittrich S, Thongpaseuth V, Vanisaveth V, Phetsouvanh R, Phompida S, et al. Therapeutic efficacy of artemether-lumefantrine and artesunate-mefloquine for treatment of uncomplicated Plasmodium falciparum malaria in Luang Namtha Province, Lao People's Democratic Republic. Trop Med Int Heal. 2004;9:1175-83.
65. Na-Bangchang K, Karbwang J, Tasanor U, Thanavibul A, Farkad E, Mull R. Pharmacokinetics of benflumetol given as a fixed combination artemether-benflumetol (CGP 56697) in Thai patients with uncomplicated falciparum malaria. Int J Clin Pharmacol Res. 1999;19:41-6.
66. Hatz C, Soto J, Nothdurft HD, Zoller T, Weitzel T, Loutan L, et al. Treatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg. 2008;78:241-7.
67. Worldwide Antimalarial Resistance Network (WWARN) AL Dose Impact Study Group. The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infect Dis. 2015;15:692-702.
68. Wojcicki JM. The double burden household in sub-Saharan Africa: maternal overweight and obesity and childhood undernutrition from the year 2000: results from World Health Organization Data (WHO) and Demographic Health Surveys (DHS). BMC Public Health. 2014;14:1124.
69. Fillol F, Cournil A, Boulanger D, Cisse B, Sokhna C, Targett G, et al. Influence of wasting and stunting at the onset of the rainy season on subsequent malaria morbidity among rural preschool children in Senegal. Am J Trop Med Hyg. 2009;80:202-8.
70. Friedman JF, Kwena AM, Mirel LB, Kariuki SK, Terlouw DJ, Phillips-Howard PA, et al. Malaria and nutritional status among pre-school children: results from cross-sectional surveys in western Kenya. Am J Trop Med Hyg. 2005;73:698-704.
71. Genton B, Al-Yaman F, Ginny M, Taraika J, Alpers MP. Relation of anthropometry to malaria morbidity and immunity in Papua New Guinean children. Am J Clin Nutr. 1998;68:734-41.
72. Olanrewaju WI, Johnson AW. Chloroquine-resistant Plasmodium falciparum malaria in Ilorin, Nigeria: prevalence and risk factors for treatment failure. Afr J Med Med Sci. 2001;30:165-9.
73. Sapak P, Garner P, Baea M, Narara A, Heywood P, Alpers M. Ineffectiveness of amodiaquine against Plasmodium falciparum malaria in symptomatic young children living in an endemic malarious area of Papua New Guinea. J Trop Pediatr. 1991;37:185-90.
74. Verret WJ, Arinaitwe E, Wanzira H, Bigira V, Kakuru A, Kamya M, et al. Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malaria. Antimicrob Agents Chemother. 2011;55:2629-35.
75. Wolday D, Kibreab T, Bukenya D, Hodes R. Sensitivity of Plasmodium falciparum in vivo to chloroquine and pyrimethamine-sulfadoxine in Rwandan patients in a refugee camp in Zaire. Trans R Soc Trop Med Hyg. 1995;89:654-6.
76. Oshikoya KA, Senbanjo IO. Pathophysiological changes that affect drug disposition in protein-energy malnourished children. Nutr Metab. 2009;6:50.
77. Gera T, Sachdev HP. Effect of iron supplementation on incidence of infectious illness in children: systematic review. Br Med J. 2002;325:1142.
78. Nussenblatt V, Semba RD. Micronutrient malnutrition and the pathogenesis of malarial anemia. Acta Trop. 2002;82:321-37.
79. Gorstein J, Sullivan K, Yip R, de Onis M, Trowbridge F, Fajans P, et al. Issues in the assessment of nutritional status using anthropometry. Bull World Heal Organ. 1994;72:273-83.
80. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J. 2009;8:253.
81. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619-20.
82. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455-67.
83. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;21:14-31.
84. Ezzet F, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. Br J Clin Pharmacol. 1998;46:553-61.
85. Hietala SF, Martensson A, Ngasala B, Dahlstrom S, Lindegardh N, Annerberg A, et al. Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2010;54:4780-8.
86. Carrara VI, Lwin KM, Phyo AP, Ashley E, Wiladphaingern J, Sriprawat K, et al. Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study. PLoS Med. 2013;10:e1001398.
87. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet. 2012;379:1960-6.
88. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411-23.
89. Huang L, Li X, Marzan F, Lizak PS, Aweeka FT. Determination of lumefantrine in small-volume human plasma by LC-MS/MS: using a deuterated lumefantrine to overcome matrix effect and ionization saturation. Bioanalysis. 2012;4:157-66.
90. World Health Organization (WHO)/WorldWide Antimalarial Resistance Network WWARN. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies. 2010. Geneva: WHO; 2011. http://apps.who.int/iris/bitstream/10665/44653/1/9789241502061_eng.pdf.
91. Lourens C, Lindegardh N, Barnes KI, Guerin PJ, Sibley CH, White NJ, et al. Benefits of a pharmacology antimalarial reference standard and proficiency testing program provided by the WorldWide Antimalarial Resistance Network (WWARN). Antimicrob Agents Chemother. 2014;58:3889-94.